ClinicalTrials.gg

TargetBeta

IL13

interleukin 13 · also P600, IL-13, ALRH, BHR1 · Interleukins

7 programs in company-led studies act on IL13, from 5 companies: 2 in phase 3, 1 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
lebrikizumabruleEli Lillyphase 4447 running–NCIt
tilrekimigPfizerphase 3119 runningIL4, TSLPthe company's pipeline
lunsekimigSanofiphase 3106 runningTSLPthe company's pipeline
zumilokibartAbbViephase 244 running–the company's pipeline
ompekimigPfizerphase 231 runningIL33, IL4the company's pipeline
GHZ339Novartisphase 211 runningIL18the company's pipeline
ABBV-313AbbViephase 111 runningIL31RAthe company's pipeline

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.